VaxForm LLC
VaxForm LLC is dedicated to developing innovative vaccine solutions, including oral COVID-19 vaccines, through research, development, and contract services. Their mission focuses on advancing vaccine technology with a strong emphasis on thermostability and mucosal delivery platforms.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Oral SARS-CoV-2 vaccine candidate
An orally administered, thermostable vaccine candidate targeting SARS-CoV-2 developed using an oral/mucosal delivery platform and stabilized formulation approaches.
Oral DTaP vaccine candidate
Development of an orally administered diphtheria–tetanus–pertussis vaccine using an oral delivery platform and adjuvant incorporation to produce a thermostable oral formulation.
Vaccine candidate targeting Streptococcus pyogenes
Recombinant fusion protein vaccine candidate aimed at inducing neutralizing antibodies against Streptococcus pyogenes with demonstrated preclinical immunogenicity and stability.
Oral SARS-CoV-2 vaccine candidate
An orally administered, thermostable vaccine candidate targeting SARS-CoV-2 developed using an oral/mucosal delivery platform and stabilized formulation approaches.
Oral DTaP vaccine candidate
Development of an orally administered diphtheria–tetanus–pertussis vaccine using an oral delivery platform and adjuvant incorporation to produce a thermostable oral formulation.
Vaccine candidate targeting Streptococcus pyogenes
Recombinant fusion protein vaccine candidate aimed at inducing neutralizing antibodies against Streptococcus pyogenes with demonstrated preclinical immunogenicity and stability.
Services
Contract services including small-scale antigen fermentation and purification, formulation development with adjuvantation and stabilization, assay development, and small-scale final drug product filling.
Contract services including small-scale antigen fermentation and purification, formulation development with adjuvantation and stabilization, assay development, and small-scale final drug product filling.
Expertise Areas
- Vaccine formulation and stabilization
- Oral and mucosal vaccine delivery
- Adjuvant formulation and production
- Small-scale antigen production and fill–finish
Key Technologies
- Thermostable vaccine formulation
- Oral/mucosal delivery platforms
- mRNA lipid nanoparticle stabilization
- Recombinant protein subunit vaccine development
News & Updates
VaxForm publishes a manuscript in the journal Vaccines about the development of their oral COVID vaccine using the QYNDR platform.
VaxForm participated in the World Vaccine Congress in Washington, DC, presenting results from their Phase I clinical trial of the oral COVID-19 vaccine.
VaxForm published a manuscript in Vaccines about their Group A Streptococcus vaccine that is safe and immunogenic in rabbits.
VaxForm was awarded a Phase I SBIR grant from the National Science Foundation to support the development of their oral COVID-19 vaccine candidate.
VaxForm received $300,000 from the PA Department of Community and Economic Development to support their oral COVID-19 vaccine development.
VaxForm publishes a manuscript in the journal Vaccines about the development of their oral COVID vaccine using the QYNDR platform.
VaxForm participated in the World Vaccine Congress in Washington, DC, presenting results from their Phase I clinical trial of the oral COVID-19 vaccine.
VaxForm published a manuscript in Vaccines about their Group A Streptococcus vaccine that is safe and immunogenic in rabbits.
VaxForm was awarded a Phase I SBIR grant from the National Science Foundation to support the development of their oral COVID-19 vaccine candidate.
VaxForm received $300,000 from the PA Department of Community and Economic Development to support their oral COVID-19 vaccine development.